EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE ON LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B

Abstract

Background/Objectives: The goal of chronic hepatitis B treatment is to prevent complications and reduce the risk of death. Tenofovir disoproxil fumarate (TDF) is one of the first optimal choices to be used in the treatment of chronic hepatitis B. FibroScan and APRI are non-invasive methods to assess liver FibroScan, recommended in patients with chronic hepatitis B for treatment and follow-up. This study was performed on chronic hepatitis B patients in order to evaluate the therapeutic effect of TDF on fibrosis via combining APRI with FibroScan at 24 weeks after treatment. Patients and Methods: This study was conducted in 40 chronic hepatitis B patients who had the indication of antiviral therapy. All patients treated with TDF were evaluated for fibrosis with APRI and FibroScan before treatment and after 24 weeks of treatment. Results: At 24 weeks, normalization of ALT 67.51%, viral response of 89.96%, HBV DNA below the detection level was 65.0%. Liver fibrosis evaluated by APRI and FibroScan before and after 24 weeks treatment were 0.87 ± 0.36, and 0.31 ± 0.12 eveluated by APRI; 6.35 ± 1.65 kPa, and 3.67 ± 1.21 kPa eveluated by FibroScan. Improved liver fibrosis after 24 weeks post-treatment was 20% via combining APRI with FibroScan. Conclusions: TDF was effective for 20% of patients after 24 weeks of treatment on liver fibrosis assessed by combination of APRI and FibroScan in chronic hepatitis B patients. Key words: APRI, FibroScan, chronic hepatitis B, Tenofovir disoproxil fumarate (TDF), liver fibrosis